Theranostics in Brain Tumors

Hossein Shooli; Reza Nemati; Hojjat Ahmadzadehfar; Mariam Aboian; Esmail Jafari; Narges Jokar; Iraj Nabipour; Habibollah Dadgar; Ali Gholamrezanezhad; Mykol Larvie; Majid Assadi

doi:10.1016/j.cpet.2021.03.005

Theranostics in Brain Tumors

PET Clin. 2021 Jul;16(3):397-418. doi: 10.1016/j.cpet.2021.03.005.

Authors

Affiliations

¹ Department of Molecular Imaging and Radionuclide Therapy (MIRT), The Persian Gulf Nuclear Medicine Research Center, Bushehr Medical University Hospital, School of Medicine, Bushehr University of Medical Sciences, Moallem St, Bushehr, Iran.
² Department of Neurology, Bushehr Medical University Hospital, Bushehr University of Medical Sciences, School of Medicine, Bushehr, Iran.
³ Department of Nuclear Medicine, Klinikum Westfalen, Dortmund, Germany.
⁴ Department of Radiology, Yale University School of Medicine, New Haven, CT, USA.
⁵ Department of Internal Medicine (Division of Endocrinology), Bushehr Medical University Hospital, The Persian Gulf Tropical Medicine Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran.
⁶ Cancer Research Center, RAZAVI Hospital, Imam Reza International University, Mashhad, Iran.
⁷ Department of Diagnostic Radiology, Keck School of Medicine, University of Southern California (USC), 1520 San Pablo Street, Suite L1600, Los Angeles, CA 90033, USA.
⁸ Department of Radiology, Cleveland Clinic, Cleveland, OH, USA.
⁹ Department of Molecular Imaging and Radionuclide Therapy (MIRT), The Persian Gulf Nuclear Medicine Research Center, Bushehr Medical University Hospital, School of Medicine, Bushehr University of Medical Sciences, Moallem St, Bushehr, Iran. Electronic address: assadipoya@yahoo.com.

PMID: 34053584
DOI: 10.1016/j.cpet.2021.03.005

Abstract

Theranostic nuclear oncology, mainly in neuro-oncology (neurotheranostics), aims to combine cancer imaging and therapy using the same targeting molecule. This approach tries to identify patients who are most likely to benefit from tumor molecular radionuclide therapy. The ability of radioneurotheranostic agents to interact with cancer cells at the molecular level with high specificity can significantly improve the effectiveness of cancer therapy. A variety of biologic targets are under investigation for treating brain tumors. PET-based precision imaging can substantially improve the therapeutic efficacy of radiotheranostic approach in brain tumors.

Keywords: Brain tumor; Neuro-oncology; Neurotheranostics; PET/CT; PET/MR imaging; Radioneurotheranostics; Theranostics.

Publication types

Review

MeSH terms

Brain Neoplasms* / diagnostic imaging
Brain Neoplasms* / therapy
Diagnostic Imaging
Humans
Medical Oncology
Precision Medicine*
Theranostic Nanomedicine